# Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

> **NCT03482102** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 37 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Biliary Tract Cancer

## Interventions

- **DRUG:** Tremelimumab
- **DRUG:** Durvalumab
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03482102
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-14
- **Primary completion:** 2024-02-28
- **Final completion:** 2026-04-30
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03482102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03482102, "Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03482102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*